ZNF703 and neoplasm: Furthermore, the in vivo antitumor assay demonstrated that tumor load in both control+sorafenib and shZNF703+sorafenib groups were significantly decreased compared to those in control and shZNF703 groups, which indicated that ZNF703 depletion increased the effect of Sorafenib on subcutaneous tumor growth (Fig. 7C).